Therefore an optimal treatment sequencing strategy for BRAF-mutated patients is still a matter of debate while final data from clinical trials like DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing; ECOG-ACRIN EA6134; NCT02224781) and SECOMBIT (Sequential Combo Immuno and Target Therapy; NCT02631447) are awaited [4]. The gene discussed is BRAF; the disease is melanoma.